In our weekly check, Generate Biomedicines, Inc. is graded D (A to F). Of 15 checks on debt, profit, cash flow and trend: 6 pass, warnings: 2, red flags: 7.
Sector: Financial Services · Asset Management
Next earnings report: 2026-11-05
NTLA · XNCR · BHVN · XERS · IMNM · TRVI
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-10-10